Sector Alpha Week of 2026-09-11
Not SEBI Registered !! Not Investment advice !!
Sector Alpha — machine-written from the numbers · Data as of 2026-09-11

Paradeep Phosphates Ltd

PARADEEP
Fertilisers

Paradeep Phosphates Ltd's earnings have outrun its stock. EPS grew +18.2% in a year against a −8.6% price move.

The sharpest disagreement: annual EPS moved +18.2% against a −8.6% price move — the market has not yet caught up with the delivery.

The price is in a confirmed uptrend (5 weeks in) while the P/E sits at the 47th percentile of its own 4-year range. Underneath, the last four quarters read improving — profit +24.0% year on year, and 118% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.

Stage
Mixed
partial read
Price
₹156
−8.6% 1Y
P/E
14.9×
47th pctile
of its own 4-year range
Revenue (Jun 26)
₹6,124 Cr
+36.0% YoY
Profit (Jun 26)
₹393 Cr
+24.0% YoY
Operating margin
12.0%
−1.0 pp YoY
ROCE
15%
FY26
Cash conversion
118%
of profit, last 3 FY
Withheld from this page: Part of this page is deliberately not drawn: its two data sources disagree by up to 24% on reported income across 14 comparable periods, so nothing from the second source is placed here — the PEG ratio and its quarterly curve, the quarterly return curves, the annual return-on-invested-capital overlay, the total-debt and debt-to-equity series and the F-score and the return-on-invested-capital reading are absent for that reason. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data. The quarterly history also begins where the primary source begins: 6 earlier quarters the second source carries are not spliced in front of it. Extending a reported profit series is stricter than showing a ratio chart — it needs a source that has been checked.
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Paradeep Phosphates Ltd trades at ₹156, in a confirmed uptrend and 5 weeks into that stage. That is +10.1% against its own 200-day average. It sits at 70% of a 52-week range of ₹105 to ₹178. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 22 straight weeks.

Today the stock is in a confirmed uptrend — week 5 of stage 2, confirmed. At ₹156 it trades +10.1% versus its 200-day average and sits at 70% of its 52-week range (₹105–₹178).

Sep 26: ₹156 Weekly closing price (₹) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
+10.1% versus the 200-day line, week 5 of stage 2
Price50-day avg200-day avg
S2S2S4₹238₹190₹142₹94.0₹46.1₹156₹142Sep 23Jun 24Mar 25Dec 25Sep 26
S2S2S4₹238₹190₹142₹94.0₹46.1₹156₹142Sep 23Mar 25Sep 26
Beating or trailing, week by week since 2022 Each cell is one week from 2022 to now (228 weeks): the stock's trailing 13-week return minus the NIFTY 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the NIFTY 500 reading is not held.
trailing 13-week return vs the NIFTY 500
May 22Sep 26

Against the market, two honest reads. Cumulative: over the last 4.3 years the stock moved +255% while the NIFTY 500 moved +62% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 22 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Paradeep Phosphates Ltd trades at 14.9× P/E, mid-range by its own standards (47th percentile). Its long-run median P/E is 15.5×, measured across 4.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 14.9× is mid-range by its own standards (47th percentile), against a long-run median of 15.5× measured over 4.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

P/E 14.9× vs a 15.5× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly (right axis). 4.3-year window; loss-period spikes above 47× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
mid-range by its own standards (47th percentile)
P/EMedianEPS (TTM) (quarterly)
50.2×₹40737.7×₹30525.1×₹20312.6×₹1020.0×₹0.0×13.70×₹11May 22Jun 23Aug 24Sep 25Sep 26
50.2×₹40737.7×₹30525.1×₹20312.6×₹1020.0×₹0.0×13.70×₹11May 22Aug 24Sep 26
P/E
14.9×
47th percentile of 4y

Why the multiple sits where it does: over the past year annual EPS moved +18.2% against a −8.6% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 3y, of the +29.1%/yr price move, ~+96.9%/yr came from earnings growth and ~−67.8 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 24% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

03 · What the price assumes

What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.

Solved at its 13 June 2026 price, Paradeep Phosphates Ltd was paying for profit growth of about 4.5% a year. Profit itself has compounded 30.0% a year over the past 7 years. Today the market pays 14.9× P/E, the 47th percentile of its own 4-year range.

What the two numbers say together. The multiple is unremarkable against its own past, and the growth the price is paying for is below what this company has actually delivered.

How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.

04 · Stage: Mixed

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Paradeep Phosphates Ltd reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE lifting at 15.0% — the per-curve reads carry the story. The read is built from 8 quarters across 4 curves, on partial evidence.

Growth, year by year: revenue +28.7% in FY26, profit +50.5% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn. Turnaround-year spikes shown pinned (▲).
Revenue YoYProfit YoYEPS YoY
76%332%52%216%28%101%4.2%−15%−20%−130%%%28.7%50.5%FY19FY22FY26
76%332%52%216%28%101%4.2%−15%−20%−130%%%28.7%50.5%FY19FY22FY26
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. Base-effect spikes shown pinned (▲). A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue rolling over, profit rolling over
RevenueProfitEPS
81%324%54%236%27%148%0.0%60%−27%−28%%%28.1%12.6%−4%Sep 23Dec 24Jun 26
81%324%54%236%27%148%0.0%60%−27%−28%%%28.1%12.6%−4%Sep 23Dec 24Jun 26
ROCE Annual readings — the quarterly balance-sheet pieces this curve needs are not held for this stock, so the returns read moves once a year and carries less weight in the call.
the return curve, annual readings
ROCE
16%13%11%8.7%6.4%%15%FY23FY24FY26
16%13%11%8.7%6.4%%15%FY23FY24FY26
Revenue growth
Rolling over
latest +28.1% · span −19.9% to +73.7%
Profit growth
Rolling over
latest +12.6% · span +12.6% to +541.0%
EPS growth
Falling
latest −4.0% · span −4.0% to +540.7%
ROCE
Rising
latest 15.0% · span 7.0%–15.0%

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; share price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+28.7%+17.8%+33.4%
Profit+50.5%+48.5%+34.9%
EPS+18.2%+37.0%−52.3%
Share price−8.6%+29.1%
Revenue YoY (Jun 26)
+36.0%
latest quarter vs a year ago
Profit YoY (Jun 26)
+24.0%
latest quarter vs a year ago
Revenue 10y
25.9%
long-run compound pace
05 · 4-Factor Sector Score

4-Factor Sector Score

49.2/100 — rank 7 of 15 in Fertilisers · 69% evidence confidence

Paradeep Phosphates Ltd scores 49.2 out of 100 against the 15 companies it is compared with in Fertilisers, ranking 7. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 18 + 13.2 + 9.4 + 8.6 = 49.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

06 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Paradeep Phosphates Ltd reported ₹6,124 Cr of revenue in the Jun 26 quarter, +36.0% year on year. That is the 8th straight quarter of year-on-year growth. Over 7 years it has compounded at 25.9% a year. The last full year, FY26, came in at ₹21,826 Cr. The last four reported quarters add to ₹23,447 Cr.

FY26 revenue came in at ₹21,826 Cr (+28.7% on the year), capping 7 years at 25.9% compound. The latest quarter (Jun 26) printed ₹6,124 Cr, +36.0% year on year — the 8th consecutive quarter of year-over-year growth.

FY26 revenue ₹21,826 Cr (+28.7% YoY) Revenue bars, ₹ Cr (left); YoY growth-% line (right). 8-year window. A bar is red when it is lower than the year before.
25.9% a year over 7 years
RevenueYoY growth
23.6k76%17.7k52%11.8k28%5.9k4.2%0−20%₹ Cr%₹21,82628.7%FY19FY22FY26
23.6k76%17.7k52%11.8k28%5.9k4.2%0−20%₹ Cr%₹21,82628.7%FY19FY22FY26
Jun 26: ₹6,124 Cr (+36.0% YoY) Quarterly revenue bars, ₹ Cr (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
8th straight quarter of growth
Revenue (quarterly)YoY growth
7.4k103%5.6k64%3.7k26%1.9k−13%0−52%₹ Cr%₹6,12436%Sep 23Dec 24Jun 26
7.4k103%5.6k64%3.7k26%1.9k−13%0−52%₹ Cr%₹6,12436%Sep 23Dec 24Jun 26

Pace check: the last four quarters averaged +28.0% growth against the decade's 25.9% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +28.1% over the last 4 quarters against +46.7%/yr over the last 8 — rolling over; TTM profit +12.6% vs +118.4%/yr — rolling over.

07 · Operating margin

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Paradeep Phosphates Ltd's operating margin is 12.0% in the Jun 26 quarter, −1.0 percentage points against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 6.0% to 11.0%. The current quarter is running above every full year in that window.

The latest quarter's operating margin is 12.0%, −1.0 pp against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 6.0%–11.0%.

🚨 Why the margin moved: operating margin went −1.1 pp year on year while gross margin went −4.6 pp — the loss came mostly from the gross line: input costs and pricing.

FY26: 10.0% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 8-year window.
within a 6.0–11.0% band over 8 years
operating marginYoY change (pp)
11%3.5%9.9%1.7%8.5%0.0%7.0%−1.7%5.6%−3.5%%%10%1%FY19FY22FY26
11%3.5%9.9%1.7%8.5%0.0%7.0%−1.7%5.6%−3.5%%%10%1%FY19FY22FY26
Jun 26: 12.0% operating margin (−1.0 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
14%8.0%12%5.3%9.5%2.7%7.5%0.0%5.4%−2.7%%%12%−1%Sep 23Dec 24Jun 26
14%8.0%12%5.3%9.5%2.7%7.5%0.0%5.4%−2.7%%%12%−1%Sep 23Dec 24Jun 26
08 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Paradeep Phosphates Ltd earned ₹393 Cr of net profit in the Jun 26 quarter, +24.0% year on year. Full-year FY26 profit was ₹996 Cr. The 7-year compound rate is 30.0%. That is 6.4% of the quarter's revenue. The same quarter a year earlier earned ₹317 Cr.

Jun 26 profit was ₹393 Cr, +24.0% year on year. On the full year, FY26 printed ₹996 Cr (+50.5%), and the 7-year compound rate is 30.0%.

FY26 profit ₹996 Cr (+50.5% YoY) Net profit bars, ₹ Cr (left); YoY growth-% line (right). 8-year window. A bar is red when it is lower than the year before.
30.0% a year over 7 years
Net profitYoY growth
1.1k612%807430%538247%26965%0−117%₹ Cr%₹99650.5%FY19FY22FY26
1.1k612%807430%538247%26965%0−117%₹ Cr%₹99650.5%FY19FY22FY26
Jun 26: ₹393 Cr (+24.0% YoY) Quarterly net profit bars, ₹ Cr (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)YoY growth
4246,742%3184,921%2123,100%1061,279%0−542%₹ Cr%₹39324%Sep 23Dec 24Jun 26
4246,742%3184,921%2123,100%1061,279%0−542%₹ Cr%₹39324%Sep 23Dec 24Jun 26

Why profit moved: revenue contributed +36.0% and the margin −1.0 pp — the quarter was revenue-led, with the margin roughly flat.

Pace comparison, last four quarters: profit +9.0% vs revenue +28.0%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

09 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 118% of Paradeep Phosphates Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹−1,012 Cr of operating cash against ₹996 Cr of profit. After ₹1,075 Cr of capital spending, ₹−2,087 Cr was left as free cash.

FY26: operating cash of ₹−1,012 Cr against reported profit of ₹996 Cr, leaving free cash of ₹−2,087 Cr after ₹1,075 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 118% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY26: CFO ₹−1,012 Cr vs profit ₹996 Cr Operating cash flow and net profit by fiscal year, ₹ Cr; the line is free cash flow (CFO minus capital spending). 8-year window, annual resolution.
118% of 3-year profit arrived as cash
Operating cashNet profitFree cash
2.1k352−1.4k−3.2k−5.0k₹ Cr₹−1,012₹996₹−2,087FY19FY22FY26
2.1k352−1.4k−3.2k−5.0k₹ Cr₹−1,012₹996₹−2,087FY19FY22FY26
FY26: CFO = −102% of profit (three-year rate 118%) Operating cash as a share of net profit, per fiscal year, % (line). Dashed line = 100% — every unit of profit arriving as cash; outlier years shown pinned.
Conversion100%
387%73%−241%−555%−869%%−102%FY19FY22FY26
387%73%−241%−555%−869%%−102%FY19FY22FY26

Why conversion sits at 118%: the cash cycle stretched 37 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.

Router verdict: the bigger cash user is investment — capital spending ran 4.0× depreciation over three years, so the next section's job is to check what that build-out is buying.

10 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Paradeep Phosphates Ltd's cash conversion cycle runs 115 days in FY26, up from 78 days in FY21. Capital spending ran ₹3,839 Cr over the last 3 years. At FY26 sales of ₹21,826 Cr each day of that cycle holds about ₹59.8 Cr, so roughly ₹6,877 Cr sits inside the business at any moment.

FY26: debtors at 80 days, inventory at 105 days — roughly 3.5 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 115 days, looser than FY21's 78.

The full loop: cash goes out to suppliers and production on day 0; stock waits 105 days to sell; customers pay about 80 days after that; and suppliers themselves are paid at 70 days — netting out to the 115-day cycle.

In money terms: at FY26 sales of ₹21,826 Cr, each day of the cycle holds about ₹59.8 Cr — so the 115-day loop keeps roughly ₹6,877 Cr sitting inside the business at any moment.

FY26: a 115-day cash cycle Debtor days, inventory days, payable days and the cash conversion cycle by fiscal year. 8-year window.
+37 days vs FY21
Cash cycleInventory daysDebtor daysPayable days
2992301619223days115d105d80d70dFY19FY20FY22FY24FY26
2992301619223days115d105d80d70dFY19FY22FY26

On the investment side: capital spending of ₹3,839 Cr over the last 3 fiscal years against ₹958 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹424 Cr (FY26) — capacity paid for but not yet earning.

FY26: capex ₹1,075 Cr, work-in-progress ₹424 Cr Capital spending per fiscal year, ₹ Cr (bars); capital work-in-progress, ₹ Cr (line). Quarterly capital-spending history is not held for India — annual is the honest resolution.
a build-out
CapexWork-in-progress
2.5k1.9k1.3k6260₹ Cr₹1,075₹424FY20FY21FY23FY24FY26
2.5k1.9k1.3k6260₹ Cr₹1,075₹424FY20FY23FY26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

11 · Return on capital

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Paradeep Phosphates Ltd earns a ROCE of 15% in FY26. That is up from a trough of 7% in FY24. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 4.6% net margin on 1.22× asset turns.

FY26 ROCE is 15%, recovered from a FY24 trough of 7% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 4.6% net margin × 1.22× asset turns × 2.64× balance-sheet leverage ≈ 14.8% on equity. Margin does its share; leverage is a meaningful part of the equation.

FY26: ROCE 15% Return on capital employed by fiscal year, % (line). 7-year window, dips included. Dashed line = the 12.0% cost of capital used on this page.
the climb back from FY24's 7%
ROCEWACC
16%13%11%8.7%6.4%%15%FY20FY21FY23FY24FY26
16%13%11%8.7%6.4%%15%FY20FY23FY26

The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 24% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Paradeep Phosphates Ltd carries ₹6,906 Cr of borrowings against ₹6,783 Cr of equity in FY26, a debt-to-equity of 1.02. Operating profit covers the interest bill 4×. Over 5 years borrowings went from ₹1,251 Cr to ₹6,906 Cr. Capital spending ran ₹3,839 Cr across the last 3 of those years.

FY26: borrowings of ₹6,906 Cr against equity of ₹6,783 Cr — a debt-to-equity of 1.02. Operating profit covers the interest bill 4×. Over 5 years borrowings went from ₹1,251 Cr to ₹6,906 Cr while capital spending ran ₹3,839 Cr in just the last 3 — part of the build-out is riding on borrowed money.

FY26: borrowings ₹6,906 Cr at 1.02× equity Borrowings by fiscal year, ₹ Cr (bars); debt-to-equity, × (line). 8-year window. Quarterly balance-sheet history is not held for India — annual is the honest resolution.
the debt trajectory
BorrowingsDebt-to-equity
7.5k2.2×5.6k1.8×3.7k1.4×1.9k1.0×00.6×₹ Cr×₹6,9061.02×FY19FY20FY22FY24FY26
7.5k2.2×5.6k1.8×3.7k1.4×1.9k1.0×00.6×₹ Cr×₹6,9061.02×FY19FY22FY26

The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 24% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

13 · Ownership

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Domestic institutions cut 8.8 points of Paradeep Phosphates Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 18.1% of the company. Foreign institutions moved +3.2 points over the same window, to 5.1%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Domestic institutions: −8.8 points over 8 quarters to 18.1%; Foreign institutions: +3.2 points over 8 quarters to 5.1%; Promoters: +1.8 points over 8 quarters to 57.9%.

Why the register moved: rotation — foreign institutions +3.2 points against domestic institutions −8.8 points over 8 quarters, with promoters +1.8 points — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.

Fiscal-year ends: promoters +1.7 pts from Mar 24 to Mar 26 Shareholding at each fiscal-year end (March quarter), % of the company. 3 year-ends held.
PromotersForeign inst.Domestic inst.Public
62%46%30%13%−2.9%%57.8%8.4%15.5%18.3%Mar 24Mar 25Mar 26
62%46%30%13%−2.9%%57.8%8.4%15.5%18.3%Mar 24Mar 25Mar 26
Domestic institutions cut 8.8 points over 8 quarters Shareholding by holder class, % of the company, quarterly, last 13 quarters.
PromotersForeign inst.Domestic inst.Public
62%46%30%13%−2.9%%57.9%5.1%18.1%18.9%Jun 23Dec 24Jun 26
62%46%30%13%−2.9%%57.9%5.1%18.1%18.9%Jun 23Dec 24Jun 26
14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Paradeep Phosphates Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

15 · Related companies · Fertilisers
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Krishana Phoschem LtdKRISHANA 79.8/100Favorable setup100% evidence LEADER 29.8/35 Revenue 73.3% · PAT 92.2% · OPM change 0 pp 100% evidence 19.0/25 ROCE 27.2% · OPM 17% 100% evidence 12.1/20 P/E 28.2× · PEG 0.58 100% evidence 18.9/20 RS sector 43.9% · RS bench 47% · 1Y 58.7%12 of 12 weeks ahead 100% evidence
Exact sum: 29.8 + 19 + 12.1 + 18.9 = 79.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
2Gujarat Narmada Valley Fertilizers & Chemicals LtdGNFC 71.9/100Favorable setup100% evidence LEADER 25.3/35 Revenue 12.6% · PAT 84.5% · OPM change 16.1 pp 100% evidence 13.4/25 ROCE 12% · OPM 18% 100% evidence 15.5/20 P/E 8× · PEG 0.27 100% evidence 17.7/20 RS sector 12.6% · RS bench 15.2% · 1Y 11.5%9 of 12 weeks ahead 100% evidence
Exact sum: 25.3 + 13.4 + 15.5 + 17.7 = 71.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3Madhya Bharat Agro Products LtdMBAPL 64.1/100Mixed-positive evidence100% evidence LEADER 25.0/35 Revenue 47.6% · PAT 100% · OPM change 2 pp 100% evidence 16.1/25 ROCE 19.3% · OPM 16% 100% evidence 3.0/20 P/E 45.5× · PEG 2.04 100% evidence 20.0/20 RS sector 50.9% · RS bench 54.6% · 1Y 93.3%12 of 12 weeks ahead 100% evidence
Exact sum: 25 + 16.1 + 3 + 20 = 64.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4Chambal Fertilisers & Chemicals LtdCHAMBLFERT 59.7/100Mixed-positive evidence100% evidence ASLEEP 17.9/35 Revenue 15.6% · PAT 10.2% · OPM change 3 pp 100% evidence 19.3/25 ROCE 25.2% · OPM 16% 100% evidence 17.2/20 P/E 8.7× · PEG 0.52 100% evidence 5.3/20 RS sector -9.2% · RS bench -7% · 1Y -24.3%0 of 12 weeks ahead 100% evidence
Exact sum: 17.9 + 19.3 + 17.2 + 5.3 = 59.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5Rashtriya Chemicals & Fertilizers LtdRCF 53.3/100Mixed-positive evidence94% evidence ASLEEP 25.0/35 Revenue 17.5% · PAT 56.8% · OPM change 1.3 pp 100% evidence 7.8/25 ROCE 10.4% · OPM 6% 100% evidence 12.9/20 P/E 14.8× · PEG 0.9 100% evidence 7.6/20 RS sector -3.1% · RS bench -14.8% · 1Y -29.2%1 of 10 weeks ahead 70% evidence
Exact sum: 25 + 7.8 + 12.9 + 7.6 = 53.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Khaitan Chemicals & Fertilizers LtdKHAICHEM 50.5/100Mixed-positive evidence74% evidence BASING 21.6/35 Revenue 19.9% · PAT 32.5% · OPM change -3 pp 95% evidence 15.6/25 ROCE 18.5% · OPM 11% 95% evidence 10.3/20 P/E 9× · PEG — 15% evidence 3.0/20 RS sector -31.3% · RS bench -20.8% · 1Y -56.5%1 of 10 weeks ahead 70% evidence
Exact sum: 21.6 + 15.6 + 10.3 + 3 = 50.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
7Paradeep Phosphates Ltdthis pagePARADEEP 49.2/100Mixed-negative evidence69% evidence BREAKING OUT 18.0/35 Revenue 28.1% · PAT 12.6% · OPM change -1 pp 95% evidence 13.2/25 ROCE 15.4% · OPM 12% 76% evidence 9.4/20 P/E 14.9× · PEG — 15% evidence 8.6/20 RS sector -12.4% · RS bench 10.4% · 1Y -22.4%9 of 10 weeks ahead 70% evidence
Exact sum: 18 + 13.2 + 9.4 + 8.6 = 49.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8Zuari Agro Chemicals LtdZUARI 48.3/100Mixed-negative evidence87% evidence TURNING 17.3/35 Revenue -44% · PAT 100% · OPM change -1 pp 95% evidence 10.5/25 ROCE 16.4% · OPM 10% 95% evidence 14.6/20 P/E 3× · PEG — 50% evidence 5.9/20 RS sector -11.5% · RS bench -9.5% · 1Y -23.7%3 of 12 weeks ahead 100% evidence
Exact sum: 17.3 + 10.5 + 14.6 + 5.9 = 48.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
9Gujarat State Fertilizers & Chemicals LtdGSFC 47.7/100Mixed-negative evidence94% evidence BASING 18.4/35 Revenue 29.2% · PAT 7.8% · OPM change -3 pp 100% evidence 6.0/25 ROCE 7.2% · OPM 6% 100% evidence 15.8/20 P/E 9× · PEG 0.3 100% evidence 7.5/20 RS sector -5.5% · RS bench -8.1% · 1Y -27.1%0 of 10 weeks ahead 70% evidence
Exact sum: 18.4 + 6 + 15.8 + 7.5 = 47.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10Southern Petrochemicals Industries Corporation LtdSPIC 46.2/100Mixed-negative evidence80% evidence TURNING 11.2/35 Revenue -2.9% · PAT 28.3% · OPM change -5 pp 95% evidence 14.4/25 ROCE 16.8% · OPM 7% 95% evidence 11.3/20 P/E 6.9× · PEG — 15% evidence 9.3/20 RS sector -8.1% · RS bench -6.2% · 1Y -40.4%2 of 12 weeks ahead 100% evidence
Exact sum: 11.2 + 14.4 + 11.3 + 9.3 = 46.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
11Deepak Fertilisers & Petrochemicals Corp LtdDEEPAKFERT 45.7/100Mixed-negative evidence100% evidence ASLEEP 13.5/35 Revenue 13.6% · PAT -0.5% · OPM change 7 pp 100% evidence 12.1/25 ROCE 11.4% · OPM 26% 100% evidence 11.1/20 P/E 16.9× · PEG 0.57 100% evidence 9.0/20 RS sector -0.5% · RS bench 1.4% · 1Y -5.9%8 of 12 weeks ahead 100% evidence
Exact sum: 13.5 + 12.1 + 11.1 + 9 = 45.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
12Coromandel International LtdCOROMANDEL 45.5/100Mixed-negative evidence94% evidence FADING 14.0/35 Revenue 23.5% · PAT -20.9% · OPM change -2 pp 100% evidence 17.2/25 ROCE 22% · OPM 9% 100% evidence 1.9/20 P/E 30.5× · PEG 2.69 100% evidence 12.4/20 RS sector 5% · RS bench -7.1% · 1Y -14.6%4 of 10 weeks ahead 70% evidence
Exact sum: 14 + 17.2 + 1.9 + 12.4 = 45.5 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
13National Fertilizer LtdNFL 40.9/100Mixed-negative evidence84% evidence ASLEEP 24.5/35 Revenue 23.3% · PAT 100% · OPM change 3.7 pp 74% evidence 4.1/25 ROCE 9.1% · OPM 6% 100% evidence 10.0/20 P/E 9.2× · PEG 1.39 65% evidence 2.3/20 RS sector -15% · RS bench -13% · 1Y -30.8%0 of 12 weeks ahead 100% evidence
Exact sum: 24.5 + 4.1 + 10 + 2.3 = 40.9 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -15% and the one-year return is -30.8%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
14Madras Fertilizers LtdMADRASFERT 29.8/100Adverse evidence74% evidence ASLEEP 4.5/35 Revenue -4.5% · PAT 4.3% · OPM change -4 pp 95% evidence 10.9/25 ROCE 14.8% · OPM 6% 95% evidence 9.9/20 P/E 12.8× · PEG — 15% evidence 4.5/20 RS sector -14.4% · RS bench -12.7% · 1Y -33.2%1 of 10 weeks ahead 70% evidence
Exact sum: 4.5 + 10.9 + 9.9 + 4.5 = 29.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
15Fertilizers & Chemicals Travancore LtdFACT 26.9/100Adverse evidence75% evidence ASLEEP 9.0/35 Revenue 32% · PAT -80% · OPM change -4.7 pp 100% evidence 3.9/25 ROCE 4.9% · OPM -2.4% 80% evidence 10.0/20 P/E — · PEG — 0% evidence 4.0/20 RS sector -9.4% · RS bench -7.3% · 1Y -21.3%1 of 12 weeks ahead 100% evidence
Exact sum: 9 + 3.9 + 10 + 4 = 26.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is Paradeep Phosphates Ltd's share price today?

Paradeep Phosphates Ltd trades at ₹156, −8.6% over the past year. The company is valued at ₹16,197 Cr. The stock sits at 70% of its 52-week range of ₹105–₹178, +10.1% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 5 weeks in. — as of 11 September 2026.

What were Paradeep Phosphates Ltd's latest quarterly results?

Paradeep Phosphates Ltd reported revenue of ₹6,124 Cr and net profit of ₹393 Cr for the Jun 26 quarter. Revenue rose 36.0% and profit rose 24.0% year on year. Earnings per share were ₹3.78. The operating margin was 12.0%, 1.0 pp lower than a year earlier. — as of 11 September 2026.

What is Paradeep Phosphates Ltd's revenue?

Paradeep Phosphates Ltd reported revenue of ₹6,124 Cr in the Jun 26 quarter, +36.0% year on year. For the full FY26 fiscal year, revenue was ₹21,826 Cr (+28.7%). Over the last 7 years revenue compounded at 25.9% a year. — as of 11 September 2026.

What is Paradeep Phosphates Ltd's profit?

Paradeep Phosphates Ltd earned ₹393 Cr of net profit in the Jun 26 quarter, +24.0% year on year. Full-year FY26 profit was ₹996 Cr. The operating margin ran 12.0% in the latest quarter. — as of 11 September 2026.

What is Paradeep Phosphates Ltd's market cap?

Paradeep Phosphates Ltd's market capitalisation is ₹16,197 Cr at a share price of ₹156. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.

What is Paradeep Phosphates Ltd's P/E ratio?

Paradeep Phosphates Ltd trades at a P/E of 14.9×, at the 47th percentile of its own 4-year range, against a long-run median of 15.5×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.

Does Paradeep Phosphates Ltd pay a dividend?

Yes — Paradeep Phosphates Ltd's dividend payout was 16% of profit in FY26, and it recorded a payout in 5 of its last 8 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.

Is Paradeep Phosphates Ltd overvalued?

On its own history, Paradeep Phosphates Ltd looks mid-range: its P/E of 14.9× sits at the 47th percentile of its 4-year range (long-run median 15.5×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.

Is Paradeep Phosphates Ltd growing?

Yes — Paradeep Phosphates Ltd is growing: latest-quarter revenue +36.0% year on year, profit +24.0%, and the margin −1.0 pp at 12.0%. The 7-year compound rates are 25.9% (revenue) and 30.0% (profit). The earnings engine currently reads: improving — as of 11 September 2026.

How is Paradeep Phosphates Ltd performing?

Paradeep Phosphates Ltd is in a confirmed uptrend, 5 weeks in. Its latest quarter's revenue rose 36.0% and profit rose 24.0% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 22 weeks. This describes what the data did, not a rating. — as of 11 September 2026.

What stage is Paradeep Phosphates Ltd in?

Mixed — no clean majority across the growth curves, ROCE lifting at 15.0% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +28.1% latest, profit growth +12.6% latest, eps growth −4.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.

Is Paradeep Phosphates Ltd in an uptrend?

Yes — the price is in a confirmed uptrend (week 5 of stage 2), trading +10.1% versus its 200-day average and at 70% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.

Is Paradeep Phosphates Ltd beating the market?

On recent form, yes — Paradeep Phosphates Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 22 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 4.3 years the stock moved +255% against the NIFTY 500's +62% — ahead of the index over the full window. — as of 11 September 2026.

Will Paradeep Phosphates Ltd's share price go up?

This page publishes no price forecast for Paradeep Phosphates Ltd. What it measures instead: the share price is ₹156, the price is in a confirmed uptrend 5 weeks in. Its P/E of 14.9× sits at the 47th percentile of its own 4-year range. — as of 11 September 2026.

Who owns Paradeep Phosphates Ltd?

Promoters hold 57.9% of Paradeep Phosphates Ltd, foreign institutions 5.1%, domestic institutions 18.1% and the public 18.9% (latest quarter). The biggest move on the register over the last two years: Domestic institutions cut 8.8 points over 8 quarters. — as of 11 September 2026.

Does Paradeep Phosphates Ltd have too much debt?

It carries real leverage — Paradeep Phosphates Ltd's debt-to-equity is 1.02, and operating profit covers the interest bill 4×. FY26 borrowings were ₹6,906 Cr against equity of ₹6,783 Cr. Read the returns on this page with that leverage in mind — as of 11 September 2026.

What is Paradeep Phosphates Ltd's capex?

Paradeep Phosphates Ltd spent ₹3,839 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹1,075 Cr, with ₹424 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.

What is Paradeep Phosphates Ltd's cash flow?

Paradeep Phosphates Ltd consumed ₹1,012 Cr of operating cash in FY26 — cash flowed out rather than in (free cash flow: ₹−2,087 Cr). Operating cash was negative while the company reported a profit of ₹996 Cr. Cash-flow resolution for India is annual. — as of 11 September 2026.

Is Paradeep Phosphates Ltd's profit real cash?

Yes — over the last 3 fiscal years, 118% of Paradeep Phosphates Ltd's reported profit arrived as operating cash. Though the latest year ran at -102% — the trend is the thing to watch. In FY26, operating cash was ₹−1,012 Cr against reported profit of ₹996 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 11 September 2026.

Where is Paradeep Phosphates Ltd in its business cycle?

Paradeep Phosphates Ltd's FY26 operating margin was 10.0%, against a 8-year band of 6.0%–11.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 12.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.

What growth does Paradeep Phosphates Ltd's price assume?

At its price on 13 June 2026, Paradeep Phosphates Ltd was priced for profit growth of about 4.5% a year. Profit itself has compounded 30.0% a year over the past 7 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.

What could break the Paradeep Phosphates Ltd story?

The sharpest disagreement: annual EPS moved +18.2% against a −8.6% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.

Is Paradeep Phosphates Ltd a stock worth studying right now?

This is not investment advice. The machine read: Paradeep Phosphates Ltd's earnings have outrun its stock. EPS grew +18.2% in a year against a −8.6% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.

Sector Alpha — machine-written from the numbers · Data as of 2026-09-11. Every chart on this page is drawn by deterministic code from the raw series — no forecasts, no price opinions, and nothing here is investment advice.

Not SEBI Registered !! Not Investment advice !!

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI